Structure-based design of small-molecule protein-protein interaction modulators: The story so far

Future Medicinal Chemistry

Volumn 6, Issue 3, 2014, Pages 343-357

  Falchi, Federico ^a   Caporuscio, Fabiana ^b   Recanatini, Maurizio ^c  

^a ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; GLYCOPROTEIN IB ALPHA; INTRINSICALLY DISORDERED PROTEIN; NAVITOCLAX; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 4; UROKINASE; VON WILLEBRAND FACTOR;

BINDING SITE; CELL DEATH; COMPLEX FORMATION; COMPUTER MODEL; CONFORMATIONAL TRANSITION; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG STRUCTURE; ENZYME ACTIVE SITE; FLUORESCENCE POLARIZATION; HIGH THROUGHPUT SCREENING; HUMAN; HYDROGEN BOND; HYDROPHOBICITY; IC 50; LIPOPHILICITY; MITOSIS SPINDLE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR LIBRARY; PHARMACOPHORE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; REVIEW; STRUCTURE ACTIVITY RELATION; VIRTUAL REALITY;

ANIMALS; COMPUTER SIMULATION; DATABASES, PHARMACEUTICAL; DRUG DESIGN; HUMANS; PROTEIN INTERACTION MAPS; PROTEINS; SMALL MOLECULE LIBRARIES;

EID: 84895491357     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.204     Document Type: Review

References (105)

1. Chène P. Drugs targeting protein-protein interactions. ChemMedChem 1(4), 400-411 (2006).
2. Zinzalla G, Thurston DE. Targeting protein-protein interactions for therapeutic intervention: A challenge for the future. Future Med. Chem. 1(1), 65-93 (2009).
3. Jones S, Thornton JM. Prediction of protein-protein interaction sites using patch analysis. J. Mol. Biol. 272(1), 133-143 (1997).
4. Ma B, Nussinov R. Trp/Met/Phe hot spots in protein-protein interactions: Potential targets in drug design. Curr. Top. Med. Chem. 7(10), 999-1005 (2007).
5. Bogan AA, Thorn KS. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 280(1), 1-9 (1998).
6. DeLano WL. Unraveling hot spots in binding interfaces: Progress and challenges. Curr. Opin. Struct. Biol. 12(1), 14-20 (2002).
7. Ma B, Elkayam T, Wolfson H, Nussinov R. Protein-protein interactions: Structurally conserved residues distinguish between binding sites and exposed protein surfaces. Proc. Natl Acad. Sci. USA 100(10), 5772-5777 (2003).
8. Meireles LMC, Dömling AS, Camacho CJ. ANCHOR: A web server and database for analysis of protein-protein interaction binding pockets for drug discovery. Nucleic Acids Res. 38, W407-W411 (2010).
9. Koes D, Khoury K, Huang Y et al. Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS ONE 7(3), e32839 (2012).
10. Koes DR, Camacho CJ. Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure. Bioinformatics 28(6), 784-791 (2012).
11. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat. Rev. Drug Discov. 3(4), 301-317 (2004).
12. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-Affinity ligands for proteins: SAR by NMR. Science 274(5292), 1531-1534 (1996).
13. Erlanson DA, Braisted AC, Raphael DR et al. Site-directed ligand discovery. Proc. Natl Acad. Sci. USA 97(17), 9367-9372 (2000).
14. Erlanson DA, Lam JW, Wiesmann C et al. In situ assembly of enzyme inhibitors using extended tethering. Nat. Biotechnol. 21(3), 308-314 (2003).
15. Villoutreix BO, Bastard K, Sperandio O et al. In silico-in vitro screening of protein-protein interactions: Towards the next generation of therapeutics. Curr. Pharm. Biotechnol. 9(2), 103-122 (2008).
16. Ritchie DW, Kemp GJ. Protein docking using spherical polar Fourier correlations. Proteins 39(2), 178-194 (2000).
17. Chen R, Weng Z. Docking unbound proteins using shape complementarity, desolvation, and electrostatics. Proteins 47(3), 281-294 (2002).
18. Dominguez C, Boelens R, Bonvin AMJJ. HADDOCK: A protein-protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc. 125(7), 1731-1737 (2003).
19. Gray JJ, Moughon S, Wang C et al. Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations. J. Mol. Biol. 331(1), 281-299 (2003).
20. Comeau SR, Gatchell DW, Vajda S, Camacho CJ. ClusPro: A fully automated algorithm for protein-protein docking. Nucleic Acids Res. 32, W96-W99 (2004).
21. Tovchigrechko A, Vakser IA. Development and testing of an automated approach to protein docking. Proteins 60(2), 296-301 (2005).
22. Kozakov D, Brenke R, Comeau SR, Vajda S. PIPER: An FFT-based protein docking program with pairwise potentials. Proteins 65(2), 392-406 (2006).
23. Lesk VI, Sternberg MJE. 3D-Garden: A system for modeling protein-protein complexes based on conformational refinement of ensembles generated with the marching cubes algorithm. Bioinformatics 24(9), 1137-1144 (2008).
24. Lyskov S, Gray JJ. The RosettaDock server for local protein-protein docking. Nucleic Acids Res. 3, W233-W238 (2008).
25. Garzon JI, Lopéz-Blanco JR, Pons C et al. FRODOCK: A new approach for fast rotational protein-protein docking. Bioinformatics 25(19), 2544-2551 (2009).
26. Roberts VA, Thompson EE, Pique ME, Perez MS, Ten Eyck LF. DOT2: Macromolecular docking with improved biophysical models. J. Comput. Chem. 34(20), 1743-1758 (2013).
27. Diller DJ, Merz KM Jr. High throughput docking for library design and library prioritization. Proteins 43(2), 113-124 (2001).
28. Alvarez JC. High-Throughput docking as a source of novel drug leads. Curr. Opin. Chem. Biol. 8(4), 365-370 (2004).
29. Leach AR, Gillet VJ, Lewis RA, Taylor R. Three-dimensional pharmacophore methods in drug discovery. J. Med. Chem. 53(2), 539-558 (2010).
30. Horvath D. Pharmacophore-based virtual screening. Methods Mol. Biol. 672, 261-298 (2011).
31. Caporuscio F, Tafi A. Pharmacophore modeling: A forty year old approach and its modern synergies. Curr. Med. Chem. 18(17), 2543-2553 (2011).
32. Brady GP Jr, Stouten PF. Fast prediction and visualization of protein binding pockets with PASS. J. Comput. Aided Mol. Des. 14(4), 383-401 (2000).
33. Laurie ATR, Jackson RM. Q-SiteFinder: An energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21(9), 1908-1916 (2005).
34. Dundas J, Ouyang Z, Tseng J, Binkowski A, Turpaz Y, Liang J. CASTp: Computed atlas of surface topography of proteins with structural and topographical mapping of functionally annotated residues. Nucleic Acids Res. 34, W116-W118 (2006).
35. Halgren T. New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 69(2), 146-148 (2007).
36. Landon MR, Lancia DR Jr, Yu J, Thiel SC, Vajda S. Identification of hot spots within druggable binding regions by computational solvent mapping of proteins. J. Med. Chem. 50(6), 1231-1240 (2007).
37. Pettit FK, Bare E, Tsai A, Bowie JU. HotPatch: A statistical approach to finding biologically relevant features on protein surfaces. J. Mol. Biol. 369(3), 863-879 (2007).
38. Weisel M, Proschak E, Schneider G. PocketPicker: Analysis of ligand binding-sites with shape descriptors. Chem. Cent. J. 1, 7 (2007).
39. Kalidas Y, Chandra N. PocketDepth: A new depth based algorithm for identification of ligand binding sites in proteins. J. Struct. Biol. 161(1), 31-42 (2008).
40. Nicola G, Smith CA, Abagyan R. New method for the assessment of all drug-like pockets across a structural genome. J. Comput. Biol. 15(3), 231-240 (2008).
41. Capra JA, Laskowski RA, Thornton JM, Singh M, Funkhouser TA. Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure. PLoS Comput. Biol. 5(12), e1000585 (2009).
42. Ghersi D, Sanchez R. EasyMIFS and SiteHound: A toolkit for the identification of ligand-binding sites in protein structures. Bioinformatics 25(23), 3185-3186 (2009).
43. Huang B. MetaPocket: A meta approach to improve protein ligand binding site prediction. OMICS 13(4), 325-330 (2009).
44. Le Guilloux V, Schmidtke P, Tuffery P. Fpocket: An open source platform for ligand pocket detection. BMC Bioinformatics 10, 168 (2009).
45. Assi SA, Tanaka T, Rabbitts TH, Fernandez-Fuentes N. PCRPi: Presaging critical residues in protein interfaces, a new computational tool to chart hot spots in protein interfaces. Nucleic Acids Res. 38(6), e86 (2010).
46. Tripathi A, Kellogg GE. A novel and efficient tool for locating and characterizing protein cavities and binding sites. Proteins 78(4), 825-842 (2010).
47. Tseng YY, Chen ZJ, Li W-H. fPOP: Footprinting functional pockets of proteins by comparative spatial patterns. Nucleic Acids Res. 38, D288-D295 (2010).
48. Geppert T, Hoy B, Wessler S, Schneider G. Context-based identification of protein-protein interfaces and 'hot-spot' residues. Chem. Biol. 18(3), 344-353 (2011).
49. Lise S, Buchan D, Pontil M, Jones DT. Predictions of hot spot residues at protein-protein interfaces using support vector machines. PLoS ONE 6(2), e16774 (2011).
50. Roche DB, Tetchner SJ, McGuffin LJ. FunFOLD: An improved automated method for the prediction of ligand binding residues using 3D models of proteins. BMC Bioinformatics 12, 160 (2011).
51. Tan KP, Varadarajan R, Madhusudhan MS. DEPTH: A web server to compute depth and predict small-molecule binding cavities in proteins. Nucleic Acids Res. 39, W242-W248 (2011).
52. Koes DR, Camacho CJ. PocketQuery: Protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res. 40, W387-W392 (2012).
53. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 450(7172), 1001-1009 (2007).
54. Grosdidier S, Totrov M, Fernández-Recio J. Computer applications for prediction of protein-protein interactions and rational drug design. Adv. Appl. Bioinform. Chem. 2, 101-123 (2009).
55. Morelli X, Hupp T. Searching for the Holy Grail; protein-protein interaction analysis and modulation. EMBO Rep. 13(10), 877-879 (2012).
56. Mullard A. Protein-protein interaction inhibitors get into the groove. Nat. Rev. Drug Discov. 11(3), 173-175 (2012).
57. Smith MC, Gestwicki JE. Features of protein-protein interactions that translate into potent inhibitors: Topology, surface area and affinity. Expert Rev. Mol. Med. 14, e16 (2012).
58. Higueruelo AP, Jubb H, Blundell TL. Protein-protein interactions as druggable targets: Recent technological advances. Curr. Opin. Pharmacol. 13(5), 791-796 (2013).
59. Wolber G, Langer T. LigandScout: 3D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model. 45(1), 160-169 (2005).
60. Dixon SL, Smondyrev AM, Knoll EH, Rao SN, Shaw DE, Friesner RA. PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des. 20(10-11), 647-671 (2006).
61. Brenk R, Naerum L, Grädler U et al. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. J. Med. Chem. 46(7), 1133-1143 (2003).
62. Fox T, Haaksma EE. Computer based screening of compound databases: 1. Preselection of benzamidine-based thrombin inhibitors. J. Comput. Aided Mol. Des. 14(5), 411-425 (2000).
63. Ahlström MM, Ridderström M, Luthman K, Zamora I. Virtual screening and scaffold hopping based on GRID molecular interaction fields. J. Chem. Inf. Model. 45(5), 1313-1323 (2005).
64. Grohmann D, Corradi V, Elbasyouny M et al. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. Chembiochem 9(6), 916-922 (2008).
65. Caporuscio F, Tafi A, González E, Manetti F, Esté JA, Botta M. A dynamic target-based pharmacophoric model mapping the CD4 binding site on HIV-1 gp120 to identify new inhibitors of gp120-CD4 protein-protein interactions. Bioorg. Med. Chem. Lett. 19(21), 6087-6091 (2009).
66. Carlson HA, Masukawa KM, Rubins K et al. Developing a dynamic pharmacophore model for HIV-1 integrase. J. Med. Chem. 43(11), 2100-2114 (2000).
67. Barillari C, Marcou G, Rognan D. Hot-spots-guided receptor-based pharmacophores (HS-Pharm): A knowledge-based approach to identify ligand-Anchoring atoms in protein cavities and prioritize structure-based pharmacophores. J. Chem. Inf. Model. 48(7), 1396-1410 (2008).
68. Tuffery P, Derreumaux P. Flexibility and binding affinity in protein-ligand, protein-protein and multi-component protein interactions: Limitations of current computational approaches. J. R. Soc. Interface. 9(66), 20-33 (2012).
69. Mukherjee P, Desai P, Zhou Y-D, Avery M. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening. J. Chem. Inf. Model. 50(5), 906-923 (2010).
70. Billard C. BH3 Mimetics: Status of the field and new developments. Mol. Cancer Ther. 12(9), 1691-1700 (2013).
71. Irwin JJ, Shoichet BK. ZINC-A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model. 45(1), 177-182 (2005).
72. Irwin JJ, Sterling T, Mysinger MM, Bolstad ES, Coleman RG. ZINC: A free tool to discover chemistry for biology. J. Chem. Inf. Model. 52(7), 1757-1768 (2012).
73. Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J. Mol. Biol. 267(3), 727-748 (1997).
74. Kortagere S, Welsh WJ, Morrisey JM et al. Structure-based design of novel small-molecule inhibitors of Plasmodium falciparum. J. Chem. Inf. Model. 50(5), 840-849 (2010).
75. Kortagere S, Welsh WJ. Development and application of hybrid structure based method for efficient screening of ligands binding to G-protein coupled receptors. J. Comput. Aided Mol. Des. 20(12), 789-802 (2006).
76. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 52(4), 609-623 (2003).
77. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1-3), 3-26 (2001).
78. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J. Med. Chem. 28(7), 849-857 (1985).
79. Corradi V, Mancini M, Manetti F, Petta S, Santucci MA, Botta M. Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14-13-13 protein-protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. Bioorg. Med. Chem. Lett. 20(20), 6133-6137 (2010).
80. Corradi V, Mancini M, Santucci MA et al. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: The 14-13-3s case. Bioorg. Med. Chem. Lett. 21(22), 6867-6871 (2011).
81. Cohen J. Virology. HIV gets by with a lot of help from human host. Science 319(5860), 143-144 (2008).
82. Christ F, Voet A, Marchand A et al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol. 6(6), 442-448 (2010).
83. Massova I, Kollman PA. Computational alanine scanning to probe protein-protein interactions: A novel approach to evaluate binding free energies. J. Am. Chem. Soc. 121(36), 8133-8143 (1999).
84. Geppert T, Bauer S, Hiss JA et al. Immunosuppressive small molecule discovered by structure-based virtual screening for inhibitors of protein-protein interactions. Angew. Chem. Int. Ed. Engl. 51(1), 258-261 (2012).
85. Löwer M, Geppert T, Schneider P, Hoy B, Wessler S, Schneider G. Inhibitors of Helicobacter pylori protease HtrA found by 'virtual ligand' screening combat bacterial invasion of epithelia. PLoS ONE 6(3), e17986 (2011).
86. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: Drugging the p53 pathway. Nat. Rev. Cancer 9(12), 862-873 (2009).
87. Murali R, Cheng X, Berezov A et al. Disabling TNF receptor signaling by induced conformational perturbation of tryptophan-107. Proc. Natl Acad. Sci. USA 102(31), 10970-10975 (2005).
88. Cai Z, Greene MI, Berezov A. Modulation of biomolecular interactions with complex-binding small molecules. Methods 46(1), 39-46 (2008).
89. Ewing TJ, Makino S, Skillman AG, Kuntz ID. DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des.15(5), 411-428 (2001).
90. Berezov A, Cai Z, Freudenberg JA et al. Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin. Oncogene 31(15), 1938-1948 (2012).
91. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 140(6), 805-820 (2010).
92. Joce C, Stahl JA, Shridhar M et al. Application of a novel in silico high-Throughput screen to identify selective inhibitors for protein-protein interactions. Bioorg. Med. Chem. Lett. 20(18), 5411-5413 (2010).
93. Khanna M, Wang F, Jo I et al. Targeting multiple conformations leads to small molecule inhibitors of the uPAR-uPA protein-protein interaction that block cancer cell invasion. ACS Chem. Biol. 6(11), 1232-1243 (2011).
94. Morris GM, Huey R, Lindstrom W et al. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 30(16), 2785-2791 (2009).
95. Hetényi C, van der Spoel D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci. 11(7), 1729-1737 (2002).
96. Friesner RA, Banks JL, Murphy RB et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47(7), 1739-1749 (2004).
97. Broos K, Trekels M, Jose RA et al. Identification of a small molecule that modulates platelet glycoprotein Ib-von Willebrand factor interaction. J. Biol. Chem. 287(12), 9461-9472 (2012).
98. Sperandio O, Reynès CH, Camproux AC, Villoutreix BO. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov. Today 15(5-6), 220-229 (2010).
99. Verdonk ML, Berdini V, Hartshorn MJ et al. Virtual screening using protein-ligand docking: Avoiding artificial enrichment. J. Chem. Inf. Comput. Sci. 44(3), 793-806 (2004).
100. Friesner RA, Murphy RB, Repasky MP et al. Extra precision Glide: Docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem. 49(21), 6177-6196 (2006).
101. Sherman W, Day T, Jacobson MP, Friesner RA, Farid R. Novel procedure for modeling ligand/receptor induced fit effects. J. Med. Chem. 49(2), 534-553 (2006).
102. Labbé CM, Laconde G, Kuenemann MA, Villoutreix BO, Sperandio O. iPPI-DB: A manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. Drug Discov. Today (2013).
103. Krüger DM, Jessen G, Gohlke H. How good are state-of-The-Art docking tools in predicting ligand binding modes in protein-protein interfaces? J. Chem. Inf. Model. 52(11), 2807-2811 (2012).
104. Masetti M, Rocchia W. Molecular mechanics and dynamics: Numerical tools to sample the configuration space. In: Frontiers in Bioscience. 19(1), 578-604 (2014).
105. Chapman HN, Fromme P, Barty A et al. Femtosecond x-ray protein nanocrystallography. Nature 470(7332), 73-77 (2011).